PMV Pharmaceuticals (PMVP) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Apr, 2026Voting matters and shareholder proposals
Election of two Class III directors: David H. Mack, Ph.D. and Laurie Stelzer, with board recommendation to vote for both.
Advisory vote on executive compensation, with board recommendation to approve.
Ratification of Ernst & Young LLP as independent public accounting firm, with board recommendation to approve.
Other business may be addressed as appropriate during the meeting or any adjournment.
Board of directors and corporate governance
Board recommends the election of two nominees to serve as Class III directors.
Executive compensation and say-on-pay
Shareholders are asked to approve, on a non-binding advisory basis, the compensation of named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from PMV Pharmaceuticals
- Interim phase II data for Y220C p53 solid tumors expected July-August, with robust enrollment.PMVP
TD Cowen's 6th Annual Oncology Innovation Summit30 Jun 2026 - Directors elected, executive pay approved, and auditor ratified; all proposals passed.PMVP
AGM 20264 Jun 2026 - Q1 2026 net loss was $18.0M; cash runway extends through Q2 2027 as rezatapopt advances in trials.PMVP
Q1 202612 May 2026 - Rezatapopt shows 46% ORR in ovarian cancer; NDA submission planned for Q1 2027.PMVP
TD Cowen 46th Annual Health Care Conference5 May 2026 - Director elections, executive pay, and auditor ratification headline the annual meeting agenda.PMVP
Proxy filing22 Apr 2026 - Strong Phase 2 efficacy for rezatapopt in ovarian cancer; NDA planned Q1 2027.PMVP
Q4 20256 Mar 2026 - Rezatapopt delivers strong efficacy and safety in TP53 Y220C-mutant cancers, targeting 2027 approval.PMVP
Corporate presentation2 Mar 2026 - Interim Phase 2 data for rezatapopt will be released mid-2024, supporting a 2026 NDA filing.PMVP
Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 202517 Dec 2025 - Offering up to $200M in securities to fund oncology R&D, with Jefferies as sales agent.PMVP
Registration Filing16 Dec 2025